Abstract
Introduction: With decline of glomerular filtration rate (GFR), a number of metabolic bone diseases such as osteoporosis are simultaneously caused. We evaluated the results of alendronate on bone density in patients with chronic kidney disease (CKD).
Objectives: The main aim of the study was evaluation of the changes in bone density, one year after treatment by dual energy x-ray absorptiometry technique.
Patients and Methods: We evaluated two treatment regimens on bone density of 44 patients between 18-45 years old (22 in experimental and 22 in control group) in a controlled double blind randomized trial. The experimental group was prescribed alendronate (10 mg), calcitriol (0.25 μg) and calcium carbonate (1500 mg) daily. The control group was treated with the same regimen except for alendronate.
Results: After completion of the trial, bone density decreased in all patients in the control group, but increased in the experimental group, in lumbar spine and femoral neck, 6.4% and 4.5% respectively. Alendronate was well tolerated.
Conclusion: Alendronate is safe in these patients and increases the bone density in CKD stage 1 and 2.
Keywords: Alendronate; Bone density; Chronic kidney disease